Development and use of integral assays in clinical trials (Q35838558)

10 August 2017

Development and use of integral assays in clinical trials (English)

1 reference

10 August 2017

Richard L Schilsky

1

1 reference

10 August 2017

James H Doroshow

series ordinal

2

1 reference

10 August 2017

Michael Leblanc

series ordinal

3

1 reference

10 August 2017

Barbara A Conley

series ordinal

4

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 March 2012

1 reference

10 August 2017

Clinical Cancer Research

1 reference

10 August 2017

18

1 reference

10 August 2017

1540-1546

1 reference

10 August 2017

6

1 reference

Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3307146

Bridging the gap: moving predictive and prognostic assays from research to clinical use

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3307146

Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3307146

Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3307146

Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3307146

Randomized clinical trials with biomarkers: design issues

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3307146

A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3307146

Use of archived specimens in evaluation of prognostic and predictive biomarkers

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3307146

Targeting the eicosanoid pathway in non-small-cell lung cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3307146

Validation of analytic methods for biomarkers used in drug development

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3307146

Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3307146

A cost-effectiveness approach to the qualification and acceptance of biomarkers

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3307146

Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3307146

Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3307146

Fit-for-purpose method development and validation for successful biomarker measurement.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3307146

Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3307146

Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress

24 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22422406

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22422406

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22422406

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1078-0432.CCR-11-2202

1 reference

10 August 2017

1 reference

10 August 2017

1 reference